Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar-Apr;27(2):e14430.
doi: 10.1111/tid.14430. Epub 2024 Dec 28.

Outcomes Associated With Blastomycosis in Solid Organ and Hematopoietic Cell Transplant Recipients

Vaisak O Nair  1 , Bradley Johnson  2 , Paschalis Vergidis  1 , Nischal Ranganath  1
Affiliations

Outcomes Associated With Blastomycosis in Solid Organ and Hematopoietic Cell Transplant Recipients

Vaisak O Nair et al. Transpl Infect Dis. 2025 Mar-Apr.

Abstract

Introduction: With reports of expanding epidemiology of blastomycosis across the United States, the purpose of this study was to evaluate the incidence and outcomes associated with blastomycosis in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients.

Methods: We conducted a retrospective case series of adult SOT and HCT recipients at a tertiary care medical center between January 1, 2005 and September 30, 2023. Cases were defined as culture-proven blastomycosis. We performed descriptive statistical analysis to evaluate diagnosis, management, and outcomes (mortality) of blastomycosis in SOT.

Results: The cumulative incidence of blastomycosis was 0.11% with a median time to infection following transplant of 743 days. Of the 19 cases, the majority of patients were SOT recipients (90%). Supratherapeutic immunosuppression within 30 days of diagnosis was observed in 42% of cases with documented drug monitoring. Urine antigen testing was highly sensitive (100%). Fourteen (73.7%) patients received induction therapy with liposomal amphotericin B followed by azole therapy for a minimum of 12 months. Despite appropriate treatment, 1-year mortality was high at 26.3%, with attributable mortality of 21.1%.

Conclusions: While rates of blastomycosis remain low among SOT and HCT recipients, infection is associated with poor posttransplant outcomes. Antigen testing can aid in timely assessment of disease severity and initiation of appropriate therapy. Among survivors, no relapses were observed while on lifelong secondary suppression. Future studies should aim to better define risk factors associated with developing blastomycosis and establish effective strategies for prevention.

Keywords: blastomycosis; hematopoietic cell transplantation; immunosuppression; solid organ transplantation.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. A. Austin, E. Tobin, M. A. Judson, et al., “Blastomycosis in the Capital District of New York State: A Newly Identified Emerging Endemic Area,” American Journal of Medicine 134, no. 2 (2021): e101–e108.
    1. K. Benedict, G. R. Thompson, 3rd, S. Deresinski, and T. Chiller, “Mycotic Infections Acquired Outside Areas of Known Endemicity, United States,” Emerging Infectious Diseases 21, no. 11 (2015): 1935–1941.
    1. E. M. Brown, L. R. McTaggart, D. Dunn, et al., “Epidemiology and Geographic Distribution of Blastomycosis, Histoplasmosis, and Coccidioidomycosis, Ontario, Canada, 1990–2015,” Emerging Infectious Diseases 24, no. 7 (2018): 1257–1266.
    1. J. J. Ross, S. Koo, A. E. Woolley, and R. A. Zuckerman, “Blastomycosis in New England: 5 Cases and a Review,” Open Forum Infectious Diseases 10, no. 1 (2023): ofad029.
    1. A. Carignan, C. Boudhrioua, S. Moreira, et al., “Changing Patterns of Disease Severity in Blastomyces Dermatitidis Infection,” Emerging Infectious Diseases 27, no. 11 (2021): 2810–2817.

Substances

LinkOut - more resources